Stocks
Viveve Medical Financial Statements (VIVE) |
||||||||||
| Viveve Medicalsmart-lab.ru | % | 2021Q3 | 2021Q4 | 2022Q1 | 2022Q2 | 2022Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.11.2021 | 17.03.2022 | 12.05.2022 | 11.08.2022 | 10.11.2022 | 10.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1.62 | 1.71 | 1.64 | 1.80 | 1.68 | 6.83 | |||
| Operating Income, bln rub | -5.49 | -5.99 | -5.47 | -5.02 | -4.66 | -21.1 | ||||
| EBITDA, bln rub | ? | -5.32 | -5.75 | -5.29 | -4.87 | -4.51 | -20.4 | |||
| Net profit, bln rub | ? | -5.86 | -6.33 | -6.18 | -6.12 | -5.29 | -23.9 | |||
| OCF, bln rub | ? | -2.66 | -3.23 | -5.09 | -4.57 | -3.35 | -16.2 | |||
| CAPEX, bln rub | ? | 0.084 | 0.294 | 0.049 | 0.059 | 0.193 | 0.595 | |||
| FCF, bln rub | ? | -2.75 | -3.52 | -5.14 | -4.63 | -3.54 | -16.8 | |||
| Dividend payout, bln rub | 0.000 | 4.69 | 0.000 | 0.000 | 0.000 | 4.69 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -19.6% | ||||
| OPEX, bln rub | 5.61 | 5.95 | 5.79 | 5.31 | 5.21 | 22.3 | ||||
| Cost of production, bln rub | 1.50 | 1.75 | 1.32 | 1.50 | 1.14 | 5.71 | ||||
| R&D, bln rub | 2.70 | 2.86 | 2.14 | 1.92 | 1.80 | 8.72 | ||||
| Interest expenses, bln rub | 0.255 | 0.266 | 0.270 | 0.284 | 0.292 | 1.11 | ||||
| Assets, bln rub | 30.4 | 25.9 | 20.7 | 15.5 | 12.2 | 12.2 | ||||
| Net Assets, bln rub | ? | 20.4 | 15.1 | 10.2 | 5.28 | 1.18 | 1.18 | |||
| Debt, bln rub | 5.18 | 5.35 | 5.52 | 5.70 | 5.88 | 5.88 | ||||
| Cash, bln rub | 22.7 | 19.2 | 14.0 | 9.43 | 5.91 | 5.91 | ||||
| Net debt, bln rub | -17.5 | -13.8 | -8.53 | -3.73 | -0.03 | -0.03 | ||||
| Ordinary share price, rub | 2.28 | 1.14 | 1.06 | 0.656 | 0.680 | 0.907 | ||||
| Number of ordinary shares, mln | 10.6 | 10.1 | 10.6 | 10.6 | 10.7 | 10.7 | ||||
| Market cap, bln rub | 24 | 12 | 11 | 7 | 7 | 10 | ||||
| EV, bln rub | ? | 7 | -2 | 3 | 3 | 7 | 10 | |||
| Book value, bln rub | 20 | 15 | 10 | 5 | 1 | 1 | ||||
| EPS, rub | ? | -0.55 | -0.63 | -0.58 | -0.58 | -0.50 | -2.24 | |||
| FCF/share, rub | -0.26 | -0.35 | -0.48 | -0.43 | -0.33 | -1.58 | ||||
| BV/share, rub | 1.92 | 1.49 | 0.96 | 0.50 | 0.11 | 0.11 | ||||
| EBITDA margin, % | ? | -329.5% | -337.3% | -322.4% | -271.4% | -267.8% | -299.2% | |||
| Net margin, % | ? | -362.5% | -370.9% | -376.4% | -341.1% | -314.1% | -350.4% | |||
| FCF yield, % | ? | -51.7% | -115.9% | -134.4% | -229.7% | -232.0% | -174.0% | |||
| ROE, % | ? | -100.4% | -146.2% | -220.7% | -464.2% | -2 020% | -2 020% | |||
| ROA, % | ? | -67.3% | -85.0% | -108.4% | -158.1% | -196.8% | -196.8% | |||
| P/E | ? | -1.18 | -0.52 | -0.50 | -0.29 | -0.30 | -0.40 | |||
| P/FCF | -1.93 | -0.86 | -0.74 | -0.44 | -0.43 | -0.57 | ||||
| P/S | ? | 3.62 | 1.79 | 1.70 | 1.03 | 1.06 | 1.42 | |||
| P/BV | ? | 1.19 | 0.76 | 1.11 | 1.32 | 6.13 | 8.17 | |||
| EV/EBITDA | ? | -0.37 | 0.12 | -0.14 | -0.15 | -0.35 | -0.47 | |||
| Debt/EBITDA | 0.96 | 0.70 | 0.43 | 0.18 | 0.00 | 0.00 | ||||
| R&D/CAPEX, % | 3 208% | 973.1% | 4 367% | 3 256% | 932.6% | 1 466% | ||||
| CAPEX/Revenue, % | 5.20% | 17.2% | 2.99% | 3.29% | 11.5% | 8.72% | ||||
| Viveve Medical shareholders | ||||||||||
